Sotera Health Company — Form 8-K Summary
Business context and reporting period
Sotera Health Company filed a Form 8-K dated May 27, 2022, reporting events from its May 26, 2022 Annual Meeting of Stockholders. The filing concerns corporate governance matters and does not report operating or financial results.
Key financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating performance metrics. A quorum was present, with holders of 266,228,143 shares representing 94.13% of the voting power as of the April 1, 2022 record date.
Material changes versus the prior comparable period
- Three Class II director nominees—Ruoxi Chen, David A. Donnini, and Ann R. Klee—were elected to three-year terms ending at the 2025 annual meeting.
- Stockholders recommended annual advisory votes on executive compensation. Consistent with its prior recommendation and the vote, the Board determined that future say-on-pay votes will occur every year.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, outlook, risks, contingencies, and unusual items
The filing provides no financial guidance, operating outlook, material risk update, litigation update, contingency disclosure, or unusual accounting item. It reports only the results of the annual meeting.
Important facts for investors to verify
- Director election vote totals: Chen—239,802,823 for; Donnini—239,860,666 for; Klee—240,814,033 for.
- The advisory vote favored a one-year executive-compensation vote by 264,927,407 votes, versus 1,399 for two years and 366,772 for three years.
- Ernst & Young’s appointment was ratified by 266,094,724 votes for, 1,535 against, and 131,884 abstentions, with no broker non-votes.
- Review the Company’s April 14, 2022 definitive proxy statement for proposal details and director information.